Please login to the form below
MSD
This page shows the latest MSD news and features for those working in and with pharma, biotech and healthcare.
AstraZeneca and Daiichi Sankyo announce results for lung cancer therapy
TROPION-Lung02 is an ongoing global, open-label trial evaluating the safety and efficacy of the antibody drug conjugate in combination with Merck’s – known as MSD outside the US and
Latest news
-
Merck and Cerevance to research novel targets in Alzheimer’s disease
A multi-year strategic research collaboration has been announced between Merck – known as MSD outside the US and Canada – and Cerevance.
-
AstraZeneca and MSD’s breast cancer drug Lynparza receives EC approval
AstraZeneca (AZ) and MSD’s – known as Merck &Co in the US and Canada – Lynparza (olaparib) has been approved by the European Commission (EC) for the treatment of patients with germline ... Lynparza, which is being jointly developed and
-
MSD and AstraZeneca announce phase 3 results for prostate cancer therapy
MSD – known as Merck &Co in the US and Canada – and AstraZeneca have shared positive results from the PROpel phase 3 trial for the combination therapy of Lynparza (olaparib) plus abiraterone
-
FDA delays Merck’s pneumococcal vaccine Vaxneuvance
Merck &Co – known as MSD outside the US and Canada – has announced that the US Food and Drug Administration (FDA) has extended the date of the company’s application for its
-
Merck’s Keytruda receives FDA approval for advanced endometrial cancer
Merck &Co – known as MSD outside the US and Canada – has announced that Keytruda (pembrolizumab) has been approved by the US Food and Drug Administration (FDA) for advanced endometrial cancer.
More from news
Approximately 83 fully matching, plus 406 partially matching documents found.
Latest Intelligence
-
Diversity in Pharma: The Impact of COVID-19 on DE&I
Meet the panel:. Andrés López Castaño, Vaccine Therapeutic Area Lead, Global LGBTQI+ ERG Lead, MSD Switzerland. ... He currently leads D&I for the Europe LGBT+ Employee Resource Network, the Zurich office as well as the Global Data Management
-
Alzheimer’s disease: the search for a cure
The companies, Abbvie, Astex Pharmaceuticals, Eisai, Johnson &Johnson, Lilly, MSD and Takeda, Evotec and Charles River, participate in research projects alongside academic scientists.
-
NICE – but not enough
A great example is Steglatro, MSD’s treatment for type 2 diabetes. ... Armed with positive NICE guidance, MSD did a great job of getting Steglatro on formulary.
-
Switzerland: a life sciences hub
The country is thus home to AbbVie, Allergan, Amgen, AstraZeneca, Bayer, Biogen, Boehringer Ingelheim, Eli Lilly, Gilead, GlaxoSmithKline, Janssen, Lundbeck, MSD (Merck Sharp &Dohme), Pfizer, Sanofi and Takeda among others.
-
Guiding star of science leads AstraZeneca to breakthrough in child tumour therapy
It is being developed in a strategic partnership with Merck &Co/MSD, formed in 2017, to maximise the potential of PARP and MEK inhibitors.
More from intelligence
Approximately 4 fully matching, plus 36 partially matching documents found.
Latest appointments
-
90TEN Medical appoints Niamh Mangan as its new managing director
Middleton moved to 90TEN from MSD and has over 13 years of both in-house and agency experience in healthcare communications, public relations and policy.
-
ENGINE MHP+Mischief bolsters healthcare comms expertise with new senior hires
She has also worked in roles at MSD, M&C Saatchi, the House of Commons and NCT.
-
GCI Health’s UK team announces three senior promotions
Before joining GCI Health, Yianni (pictured left) worked at pharmaceutical company MSD as a strategic project manager.
-
Merck & Co appoints Frank Clyburn as president, human health
Merck &Co – known as MSD outside the US and Canada – has appointed Frank Clyburn (pictured above) as president, human health.
-
Dan Russell joins Seven Stones as managing director
Pharmaceuticals, MSD and more.
More from appointments
Approximately 5 fully matching, plus 52 partially matching documents found.
Latest from PMHub
-
Lucid Group Bolster its Senior Leadership Team
The majority of Jo’s 15 years within pharma were spent at Sanofi Pasteur MSD where she held a number of senior marketing roles before moving agency-side to STEM, holding
-
Mednet Group
Johnson and Johnson. University of Leeds. Lundbeck Mind. MSD. Novo. Nordisk.
-
Onyx Health Expands with New Management Appointment
business such as Boots, the ProPharma Group and MSD.
-
HOW INNOVATION IS RESHAPING THE NORTH EAST LIFE SCIENCES LANDSCAPE
We have an enviable cluster of world class pharmaceutical manufacturers on our doorstep including Glaxo Smith Kline, MSD and Piramal Healthcare.
-
Wearables and healthcare
So impressive was the success of SCI-diabetes, the Scottish Government in collaboration with various stakeholders including MSD Healthcare Services, decided to unlock the data potential of the entire nation’s
More from PMHub
Approximately 0 fully matching, plus 15 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Country Manager, Healthcare Communications Agency, Germany
-
Highly competitive salary
- Sanofi halts recruitment for trials assessing MS treatment
- Environment: where does the pharmaceutical industry stand?
- bluebird bio reveals plans to launch two gene therapies
- Novartis reports death of two patients treated with Zolgensma
- ONS data reveals significant decrease in COVID-19 antibodies
- AstraZeneca and Daiichi Sankyo receive FDA approval for lung cancer drug
- Are we the masters or servants of omnichannel engagement?
- JCVI publishes advice on COVID-19 vaccines ahead of autumn booster campaign
- AstraZeneca and Daiichi Sankyo’s Enhertu shows significant improvement for breast cancer patients
- Gilead Sciences announce positive results for Trodelvy in breast cancer patients
- UK government to launch national mission to tackle dementia
- WHO publishes first position paper on optimising brain health
- Amgen acquires ChemoCentryx in $3.7bn cash deal
- Sanofi halts recruitment for trials assessing MS treatment
- AstraZeneca and Daiichi Sankyo announce results for lung cancer therapy
- JCVI publishes statement on London polio vaccination strategy
- Low-dose LSD looks safe for Alzheimer’s patients, but will it work?
- Michael J Fox Foundation awards Koneksa second research grant
PMHub
The Good Ideas Group
Remarkable but responsible creative work. We're most passionate about the pursuit of original, powerful ideas that our clients can harness...
Latest intelligence
- Environment: where does the pharmaceutical industry stand?
- ...
- The communication challenge of helping he next generation to be healthier
- As the pressure on the health service increases the health of the next generation is vital for everyone. How do we show positive attitudes and change behaviour while future proofing...
- Are we losing sight of what the democratisation of healthcare really looks like?
- We have a core responsibility as healthcare communicators to consistently drive for better inclusion, engagement and compliance. What does the ‘democratisation of healthcare’ really look like?...
